Preclinical News and Research

RSS

Scientists launch project to improve early autism diagnosis in preemies

An international team of researchers from Europe and Australia will contribute to MICRO-NEST, a €6 million Horizon Europe project applying innovative approaches to identify markers of autism in children born before 37 weeks of gestation.

3 Jun 2026

New technique protects pancreatic islet transplants without immunosuppressive drugs

Type 1 diabetes (T1D) is a lifelong autoimmune disorder where the immune system attacks islets, certain areas of the pancreas, and destroys cells that would otherwise produce insulin, a hormone crucial for regulating blood sugar levels.

3 Jun 2026

GLP-1 treatments may reduce knee replacement surgery rates

GLP-1 receptor agonist drugs, used for the treatment of diabetes, and more recently, weight loss, are associated with a significantly lower long term risk of knee replacement surgery as a result of osteoarthritis, finds an analysis of medical records data, published in the open access journal Regional Anesthesia & Pain Medicine.

2 Jun 2026

New PET imaging approach quantifies synaptic pathology in multiple sclerosis

A new PET imaging approach that measures synaptic density in the spinal cord provides a quantitative way to assess the brain's functional wiring in patients with multiple sclerosis.

2 Jun 2026

New PET imaging platform improves osteosarcoma surgery precision

A new end-to-end PET imaging approach for osteosarcoma can rapidly and reliably distinguish tumor tissue from normal tissue and accurately assess surgical margins in real time.

2 Jun 2026

Three-drug strategy forces pancreatic tumors into lasting regression

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing.

2 Jun 2026

Gladstone receives NIAID grant to establish the Center for PhAIge Therapy

When a bacterial infection stops responding to antibiotics, doctors have few options to treat it. Phages-viruses that naturally infect and kill bacteria-have long intrigued clinicians as a potential weapon against these infections.

2 Jun 2026

Novel theranostic approach targets aggressive neuroendocrine prostate cancer

A novel theranostic approach that targets RET -- a newly identified biomarker for neuroendocrine prostate cancer enables high-contrast PET imaging and effective, safe treatment for this highly aggressive malignancy.

2 Jun 2026

Advancing Human Muscle Models for Drug Development and Preclinical Testing

Transforming drug development, Myomaker Bio's lab-grown muscle platforms offer human-relevant models for effective preclinical testing and risk reduction.

From Myomaker Bio 2 Jun 2026

Introducing Evosep Proteomics to standardize and scale proteomics for research and drug development

Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS-based proteomics for research and pharmaceutical drug development.

From Evosep 2 Jun 2026

New PET radiotracer provides noninvasive diagnosis for primary aldosteronism

A new first-in-human study has validated a PET radiotracer that can effectively image overactive adrenal glands, offering an alternative to the highly invasive procedure currently utilized to diagnose primary aldosteronism.

1 Jun 2026

New atlas provides unprecedented overview of dendritic cell diversity across cancers

Researchers from VIB, VUB, and an international network of collaborators have created the most comprehensive single-cell atlas to date of tumor-associated dendritic cells.

1 Jun 2026

New SMArT platform improves safety of CRISPR gene editing

A team of researchers led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) has developed a new strategy to significantly improve the precision and safety of CRISPR-Cas9 gene editing in human blood stem cells, potentially overcoming one of the major barriers limiting broader clinical application of genome editing therapies.

1 Jun 2026

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 1 Jun 2026

Mesenchymal drift may explain how aging cells lose their identity

Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits during aging. The review proposes MD as a unifying framework that links multiple hallmarks of aging and highlights partial reprogramming as a potential, but still preclinical, way to counteract this process.

1 Jun 2026